What was the primary driver of Colgate-Palmolive's sales growth in the third quarter of 2002?

The primary driver of Colgate-Palmolive's sales growth in the third quarter of 2002 was a significant increase in unit volume, which rose by 6.0%. This volume growth was partially offset by the negative impact of foreign currency fluctuations.

How did the adoption of SFAS 142 affect the reported financial results?

The adoption of SFAS 142, which eliminated the amortization of goodwill and indefinite-lived intangible assets, meant that prior period results, specifically for 2001, were presented with an adjustment to reflect what they would have been without amortization. This generally leads to higher reported net income and EPS for the adjusted prior periods compared to the originally reported figures.

What are the main challenges or risks highlighted in the report, particularly concerning legal proceedings?

The company faces significant legal and tax matters in Brazil related to the acquisition of the Kolynos oral care business. These include a potential fine from the Central Bank of Brazil, a civil action seeking to annul a tax decision in favor of the seller, and a tax assessment for disallowed interest deductions and foreign exchange losses. While management believes these matters will be resolved favorably and will not materially impact the company's financial position or ongoing operations, they represent potential contingencies.

How did the company's different geographic segments perform in terms of sales and profit?

North America, Europe, and Asia/Africa all showed sales growth driven by volume. Latin America experienced sales declines due to foreign currency impacts, though volume increased. Hill's Pet Nutrition also saw robust sales and profit growth. Europe, in particular, benefited from a stronger Euro and increased margins, leading to significant profit growth.

CL 10-Q Quarterly Report Q3 FY2002 — Revenue, Net Income, EPS

Summary

Colgate-Palmolive Company reported a solid third quarter for 2002, demonstrating continued revenue growth driven by strong volume increases across most of its global segments. Net sales for the quarter rose by 3.5% to $2.38 billion, with a notable 6.0% unit volume gain, partially offset by unfavorable foreign currency movements. This top-line growth translated into a healthy 12% increase in net income to $330.7 million, or $0.57 per diluted share, up from $0.49 in the prior year period. The company also experienced an improvement in gross profit margins to 54.7%, attributed to a favorable product mix, cost reduction initiatives, and global sourcing. Operationally, the company saw strong performance in North America, Europe, and Asia/Africa, with Latin America facing headwinds from currency depreciation but still achieving volume growth. Hill's Pet Nutrition also delivered robust sales and profit increases. While selling, general, and administrative expenses as a percentage of sales saw a slight uptick, driven by increased advertising, the overall operating profit margin improved to 21.6%. The company also made progress in its adoption of new accounting standards, including SFAS 142 for goodwill and intangible assets, which no longer requires amortization but mandates impairment testing.

Key Highlights

1Net sales increased by 3.5% to $2.38 billion in Q3 2002, driven by a 6.0% increase in unit volume.
2Diluted earnings per share grew 16.3% to $0.57, compared to $0.49 in Q3 2001.
3Gross profit margin improved to 54.7% from 53.5% in the prior year's quarter, reflecting favorable product mix and cost efficiencies.
4Operating profit increased by 8% to $514.1 million, with the operating profit margin expanding to 21.6% from 20.6%.
5Strong volume growth was observed in North America (8.5%), Europe (7.0%), and Asia/Africa (4.5%), alongside a 6.5% volume increase in Hill's Pet Nutrition.
6The company adopted SFAS 142, eliminating amortization of goodwill and indefinite-lived intangibles, which impacted prior period comparisons.
7Net cash provided by operating activities increased by 14% to $1.25 billion for the nine months ended September 30, 2002.

COLGATE PALMOLIVE CO Quarterly Report for Q3 Ended Sep 30, 2002

Summary

Key Highlights

Frequently Asked Questions